Table of Contents
Hepatitis Research and Treatment
Volume 2010 (2010), Article ID 971095, 6 pages
http://dx.doi.org/10.1155/2010/971095
Research Article

Hypothyroidism in Noninterferon Treated-HCV Infected Individuals Is Associated with Abnormalities in the Regulation of Th17 Cells

1Laboratorio de Inmunobiología, Departmento de Biología Celular y Tisular, Facultad de Medicina, Universidad Nacional Autónoma (UNAM), Ciudad Universitaria, CP 04510, DF, Mexico
2Servicio de Gastroenterología, Hospital Regional Lic. Adolfo López Mateos, ISSSTE, Avenida Universidad 2050, Viveros Coyoacan, CP 04526, DF, Mexico
3Unidad de Investigación, Instituto de Oftalmología “Conde de Valenciana”, Chimalpopoca 14, CP 06800, DF, Mexico
4Departamento Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, CP 04510, DF, Mexico
5Departamento Biologìa Celular, Instituto Nacional de Cardiología “Ignacio Chávez”, Juan Badiano 1, Tlalpan, CP 14080, DF, Mexico

Received 11 August 2009; Revised 18 December 2009; Accepted 15 February 2010

Academic Editor: Alessandro Antonelli

Copyright © 2010 Luis A. Salazar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Broussolle, M. P. Steineur, F. Bailly, F. Zoulim, and C. Trépo, “Hepatitis C viral infection and thyroid diseases,” Revue de Medecine Interne, vol. 20, no. 9, pp. 766–773, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Indolfi, S. Stagi, E. Bartolini et al., “Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection,” Clinical Endocrinology, vol. 68, no. 1, pp. 117–121, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Antonelli, C. Ferri, S. M. Ferrari, M. Colaci, and P. Fallahi, “Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia,” Autoimmunity Reviews, vol. 8, no. 1, pp. 18–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Marazuela, L. García-Buey, B. González-Fernández et al., “Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-a therapy,” Clinical Endocrinology, vol. 44, no. 6, pp. 635–642, 1996. View at Google Scholar · View at Scopus
  5. L. Lyakh, G. Trinchieri, L. Provezza, G. Carra, and F. Gerosa, “Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans,” Immunological Reviews, vol. 226, no. 1, pp. 112–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Frisullo, V. Nociti, R. Iorio et al., “IL17 and IFN? production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis,” Cytokine, vol. 44, no. 1, pp. 22–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. W. B. van den Berg, P. L. van Lent, L. A. B. Joosten, S. Abdollahi-Roodsaz, and M. I. Koenders, “Amplifying elements of arthritis and joint destruction,” Annals of the Rheumatic Diseases, vol. 66, supplement 3, pp. 45–48, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Kobayashi, S. Okamoto, T. Hisamatsu et al., “IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease,” Gut, vol. 57, no. 12, pp. 1682–1689, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Imamura, K. Okunishi, H. Ohtsu et al., “Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung,” Thorax, vol. 64, no. 1, pp. 44–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. K. H. G. Mills, “Induction, function and regulation of IL-17-producing T cells,” European Journal of Immunology, vol. 38, no. 10, pp. 2636–2649, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Manel, D. Unutmaz, and D. R. Littman, “The differentiation of human T(H)-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt,” Nature Immunology, vol. 9, no. 6, pp. 641–649, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. G. Rowan, J. M. Fletcher, E. J. Ryan et al., “Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-ß,” Journal of Immunology, vol. 181, no. 7, pp. 4485–4494, 2008. View at Google Scholar · View at Scopus
  14. M. T. Brady, A. J. MacDonald, A. G. Rowan, and K. H. G. Mills, “Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes,” European Journal of Immunology, vol. 33, no. 12, pp. 3448–3457, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Antonelli, C. Ferri, and P. Fallahi, “Thyroid cancer in patients with hepatitis C infection,” Journal of the American Medical Association, vol. 281, no. 17, p. 1588, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. E. J. Bini and S. Mehandru, “Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study,” Archives of Internal Medicine, vol. 164, no. 21, pp. 2371–2376, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Rodriguez-Torres, C. F. Rios-Bedoya, G. Ortiz-Lasanta, A. M. Marxuach-Cuétara, and J. Jiménez-Rivera, “Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis,” Annals of Hepatology, vol. 7, no. 1, pp. 72–77, 2008. View at Google Scholar · View at Scopus
  18. S. Kasim and A. Bessman, “Thyroid autoimmunity in type 2 (non-insulin-dependent) diabetic patients of Caucasoid, black and Mexican origin,” Diabetologia, vol. 27, no. 1, pp. 59–61, 1984. View at Google Scholar · View at Scopus
  19. D. Sene, J.-C. Piette, and P. Cacoub, “Antiphospholipid antibodies, antiphospholipid syndrome and viral infections,” Revue de Medecine Interne, vol. 30, no. 2, pp. 135–141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Ramos-Casals, S. Muñoz, F. Medina et al., “Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry),” Journal of Rheumatology, vol. 36, no. 7, pp. 1442–1448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ramos-Casals, L.-J. Jara, F. Medina et al., “Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (The HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases,” Journal of Internal Medicine, vol. 257, no. 6, pp. 549–557, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Kisiel and W. Kryczka, “Antiphospholipid antibodies with HCV infection. Innocent proteins or risk factor?” Przegląd Lekarski, vol. 64, no. 7-8, pp. 521–524, 2007. View at Google Scholar · View at Scopus
  23. I. M. Cojocaru, M. Cojocaru, and S. A. Iacob, “High prevalence of anticardiolipin antibodies in patients with asymptomatic hepatitis C virus infection associated acute ischemic stroke,” Romanian Journal of Internal Medicine, vol. 43, no. 1-2, pp. 89–95, 2005. View at Google Scholar · View at Scopus
  24. Z. Kuloglu, A. Kansu, M. Berberoglu, P. Adiyaman, G. Öcal, and N. Girgin, “The incidence and evolution of thyroid dysfunction during interferon-α therapy in children with chronic hepatitis B infection,” Journal of Pediatric Endocrinology and Metabolism, vol. 20, no. 2, pp. 237–245, 2007. View at Google Scholar · View at Scopus
  25. E. Tartour, M. Schlumberger, T. Dorval, E. Baudin, and W. H. Fridman, “Endocrine involvement in immunotherapy,” Annales d'Endocrinologie, vol. 56, no. 2, pp. 143–148, 1995. View at Google Scholar · View at Scopus
  26. T. Vial and J. Descotes, “Immune-mediated side-effects of cytokines in humans,” Toxicology, vol. 105, no. 1, pp. 31–57, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Sartore-Bianchi, A. Soriani, R. Mattioni et al., “Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients,” Oncology Reports, vol. 12, no. 4, pp. 855–859, 2004. View at Google Scholar · View at Scopus
  28. G. Meloni, S. M. Trisolini, S. Capria et al., “How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration,” Leukemia, vol. 16, no. 10, pp. 2016–2018, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Amadi-Obi, C.-R. Yu, X. Liu et al., “TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1,” Nature Medicine, vol. 13, no. 6, pp. 711–718, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. K. A. Smith, “Interleukin-2: inception, impact, and implications,” Science, vol. 240, no. 4856, pp. 1169–1176, 1988. View at Google Scholar · View at Scopus
  31. G. Trinchieri, “Interleukin-12 and the regulation of innate resistance and adaptive immunity,” Nature Reviews Immunology, vol. 3, no. 2, pp. 133–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Cecere, F. Marotta, B. Vangieri, L. Tancredi, and A. Gattoni, “Progressive liver injury in chronic hepatitis C infection is related to altered cellular immune response and to different citokine profile,” Panminerva Medica, vol. 46, no. 3, pp. 171–187, 2004. View at Google Scholar · View at Scopus
  33. H. Kimura, S.-C. Tzou, R. Rocchi et al., “Interleukin (IL)-12-driven primary hypothyroidism: the contrasting roles of two Th1 cytokines (IL-12 and interferon-?),” Endocrinology, vol. 146, no. 8, pp. 3642–3651, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. K. I. Happel, P. J. Dubin, M. Zheng et al., “Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae,” Journal of Experimental Medicine, vol. 202, no. 6, pp. 761–769, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. L. Gaffen, J. M. Kramer, J. J. Yu, and F. Shen, “The IL-17 cytokine family,” Vitamins and Hormones, vol. 74, pp. 255–282, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Chen and J. J. O'Shea, “Regulation of IL-17 production in human lymphocytes,” Cytokine, vol. 41, no. 2, pp. 71–78, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. K. Kolls and A. Lindén, “Interleukin-17 family members and inflammation,” Immunity, vol. 21, no. 4, pp. 467–476, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. C. T. Weaver, R. D. Hatton, P. R. Mangan, and L. E. Harrington, “IL-17 family cytokines and the expanding diversity of effector T cell lineages,” Annual Review of Immunology, vol. 25, pp. 821–852, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. F. Wright, F. Bennett, B. Li et al., “The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex,” Journal of Immunology, vol. 181, no. 4, pp. 2799–2805, 2008. View at Google Scholar · View at Scopus
  40. D. Ge and Z. You, “Expression of interleukin-17RC protein in normal human tissues,” International Archives of Medicine, vol. 1, article 19, 2008. View at Publisher · View at Google Scholar
  41. L. A. Schubert, E. Jeffery, Y. Zhang, F. Ramsdell, and S. F. Ziegler, “Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation,” Journal of Biological Chemistry, vol. 276, no. 40, pp. 37672–37679, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Xu, A. Kitani, I. Fuss, and W. Strober, “Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β,” Journal of Immunology, vol. 178, no. 11, pp. 6725–6729, 2007. View at Google Scholar · View at Scopus
  43. L. Zhou, J. E. Lopes, M. M. W. Chong et al., “TGF-ß-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR?t function,” Nature, vol. 453, no. 7192, pp. 236–240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. J. R. Wilczynski, M. Radwan, and J. Kalinka, “The characterization and role of regulatory T cells in immune reactions,” Frontiers in Bioscience, vol. 13, no. 6, pp. 2266–2274, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. Z. Chen, A. Laurence, Y. Kanno et al., “Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 21, pp. 8137–8142, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. E. V. Acosta-Rodriguez, G. Napolitani, A. Lanzavecchia, and F. Sallusto, “Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells,” Nature Immunology, vol. 8, no. 9, pp. 942–949, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Nanba, M. Watanabe, N. Inoue, and Y. Iwatani, “Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease,” Thyroid, vol. 19, no. 5, pp. 495–501, 2009. View at Google Scholar · View at Scopus
  48. A. Awasthi, G. Murugaiyan, and V. K. Kuchroo, “Interplay between effector Th17 and regulatory T cells,” Journal of Clinical Immunology, vol. 28, no. 6, pp. 660–670, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. I. I. Ivanov, L. Zhou, and D. R. Littman, “Transcriptional regulation of Th17 cell differentiation,” Seminars in Immunology, vol. 19, no. 6, pp. 409–417, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Deknuydt, G. Bioley, D. Valmori, and M. Ayyoub, “IL-1β and IL-2 convert human Treg into T(H)17 cells,” Clinical Immunology, vol. 131, no. 2, pp. 298–307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. G. M. Thiele, T. L. Freeman, and L. W. Klassen, “Immunologic mechanisms of alcoholic liver injury,” Seminars in Liver Disease, vol. 24, no. 3, pp. 273–287, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Bai, Z.-R. Feng, H.-Y. Lu et al., “Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China,” Chinese Medical Journal, vol. 122, no. 1, pp. 5–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Sansonno, F. Anna Tucci, S. Sansonno et al., “B cells and HCV: an infection model of autoimmunity,” Autoimmunity Reviews, vol. 9, no. 2, pp. 93–94, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Bartolomé, E. Rodríguez-Iñigo, P. Quadros et al., “Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection,” Journal of Medical Virology, vol. 80, no. 9, pp. 1588–1594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Antonelli, C. Ferri, S. M. Ferrari et al., “Endocrine manifestations of hepatitis C virus infection,” Nature Clinical Practice Endocrinology and Metabolism, vol. 5, no. 1, pp. 26–34, 2009. View at Publisher · View at Google Scholar · View at Scopus